Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+१.७४%
१,०९४.८४
+१८.७१
+१.७४%
—१,०७६.१३१,०७९.८९१,१००.७७१,०७९.८९——
SIXC
Communications
SIXC
Communications
SIXC
-०.४२%
६०४.२१
-२.५३
-०.४२%
—६०६.७४६०६.७४६०७.९०६०२.०३——
SIXE
Energy
SIXE
Energy
SIXE
+०.०७%
१,२४९.७१
+०.८९
+०.०७%
—१,२४८.८२१,२४६.३७१,२५६.४२१,२३९.०८——
SIXI
Industrials
SIXI
Industrials
SIXI
+०.८६%
१,७३९.२६
+१४.९०
+०.८६%
—१,७२४.३६१,७३३.०२१,७४५.७५१,७२७.७६——
SIXM
Financials
SIXM
Financials
SIXM
+०.०१%
६३५.६३
+०.०४०
+०.०१%
—६३५.५९६३५.०८६३७.९६६३३.३१——
SIXR
Staples
SIXR
Staples
SIXR
+०.६१%
८४८.३२
+५.१७
+०.६१%
—८४३.१५८४२.५०८५२.७७८४०.८५——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+०.२२%
२१६.७६
+०.४७
+०.२२%
—२१६.२९२१६.२९२१७.३०२१५.२४——
SIXT
Technology
SIXT
Technology
SIXT
+२.२०%
३,३३५.१४
+७१.७३
+२.२०%
—३,२६३.४१३,२९६.२५३,३४३.६६३,२९५.४२——
SIXU
Utilities
SIXU
Utilities
SIXU
+०.०१%
९३९.३४
+०.१०
+०.०१%
—९३९.२४९४१.५७९४८.११९३९.११——
SIXV
Health care
SIXV
Health care
SIXV
+०.३८%
१,४६८.१७
+५.६१
+०.३८%
—१,४६२.५६१,४६५.०३१,४७१.५६१,४५९.६६——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.२८%
२,३८७.०९
+६.६९
+०.२८%
—२,३८०.४०२,३९४.९२२,४१२.१३२,३८६.८२——
ALNOV:EPA
Novacyt SA
€ ०.३४
+६.७९%
(+०.०२१) 1D
मे ५, १७:३५:२९ GMT+२  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
€ ०.३१
High
€ ०.३५
Low
€ ०.३१
Mkt. cap
२.४५ करोड
Avg. vol.
१.२५ लाख
Volume
५.०१ लाख
52-wk high
€ ०.७४
52-wk low
€ ०.३१
EPS
-€ ०.५०
Shares outstanding
७.२६ करोड
No. of employees
२३४
News stories
From sources across the web
TipRanks
TipRanks
·
८ घण्टा पहिले
Novacyt Updates Market on Liquidity Agreement Trades and Voting Rights
Investegate
Investegate
·
८ घण्टा पहिले
Liquidity Agreement Monthly Update and TVR
Investing.com Nigeria
Investing.com Nigeria
·
१ दिन पहिले
Earnings call transcript: Novacyt’s Q4 2025 results show growth but stock dips
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees२३४
Founded२००६ जुलाई ३
Headquarters-
Sector-
Websitenovacyt.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
२०२४ सेप्टेम्बर
२०२४ डिसेम्बर
२०२५ मार्च
२०२५ जुन
Revenue
-
-
४८.९६ लाख
४८.९६ लाख
Cost of goods sold
-
-
१६.४३ लाख
१६.४३ लाख
Cost of revenue
-
-
१६.४३ लाख
१६.४३ लाख
Research and development expenses
-
-
१०.२२ लाख
१०.२२ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
५५.०८ लाख
५५.०८ लाख
Operating expense
-
-
६४.३२ लाख
६४.३२ लाख
Total operating expenses
-
-
८०.७५ लाख
८०.७५ लाख
Operating income
-
-
-३१.७८ लाख
-३१.७८ लाख
Other non operating income
-
-
-३१.०० हजार
-३१.०० हजार
EBT including unusual items
-
-
-३५.१३ लाख
-३५.१३ लाख
EBT excluding unusual items
-
-
-३१.२० लाख
-३१.२० लाख
Income tax expense
-
-
-१.३४ लाख
-१.३४ लाख
Effective tax rate
-
-
३.८०%
३.८०%
Other operating expenses
-
-
-९७.५० हजार
-९७.५० हजार
Net income
-
-
-३१.७१ लाख
-३१.७१ लाख
Net profit margin
-
-
-६४.७६%
-६४.७६%
Earnings per share
-
-
-
-
Interest and investment income
-
-
१.७७ लाख
१.७७ लाख
Interest expense
-
-
-१.५४ लाख
-१.५४ लाख
Net interest expenses
-
-
२३.०० हजार
२३.०० हजार
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-२१.६६ लाख
-२१.६६ लाख
Gain or loss from assets sale
-
-
-१.४८ लाख
-१.४८ लाख
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer